ArticleFrontiers in public health2024
Trends of the second measles vaccine (MCV2) over time after its launch as part of routine immunization in Nigeria: a brief research report.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Uptake of the Second Dose of the Measles Vaccine and Its Determinants Among Children Aged Less Than 5 Years: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2025Pooled it
- Measles and rubella seropositivity among suspected measles cases in northwestern region of Nigeria.Journal of public health in Africa · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nigeria has one of the highest measles burdens and the lowest vaccination coverage in the world. Geographical disparity in the coverage has also been persistent. Between 2019 and 2021, the Nigerian government introduced the second Measles vaccine (MCV2) into routine immunization (RI). This study evaluated the trends of the MCV2 coverage over time across geographical zones. Methods: The monthly data on the MCV2 coverage from District Health Information Software (DHIS2) for all the health facilities in Nigeria were aggregated by the geopolitical zone, and the trend of the MCV2 coverage was analyzed over time. Results: The MCV2 coverage in each zone was approximately 20% when the MCV2 program was launched. The MCV2 coverage was higher in the northern zones (35-42%) than in the southern zones (22-31%) 1 year after the launch. Similarly, at 2.5 years, the MCV2 coverage ranged from 38 to 46% in northern zones, while in southern zones, it ranged from 23 to 37%. Discussion and conclusion: The introduction of MCV2 as part of the RI schedule potentially narrows down the health inequity in Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.